Capstone Wealth Management Group (Pennsylvania)’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Capstone Wealth Management Group (Pennsylvania)'s REGN Position: Q2 2026 in Review
Capstone Wealth Management Group (Pennsylvania) increased its Regeneron Pharmaceuticals (REGN) stake by 0.17% in Q2 2026, buying an estimated $2.04K and bringing the position to 1,739 shares worth $1.08M. The position accounts for 0.38% of the portfolio, ranked #44.
Capstone Wealth Management Group (Pennsylvania) first reported a position in REGN in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.92M in Q2 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Capstone Wealth Management Group (Pennsylvania) held 1,739 shares of Regeneron Pharmaceuticals worth $1.08M as of Q2 2026.
- Capstone Wealth Management Group (Pennsylvania) bought 3 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.04K.
- Regeneron Pharmaceuticals made up 0.38% of Capstone Wealth Management Group (Pennsylvania)'s portfolio in Q2 2026, its #44 holding.
- Capstone Wealth Management Group (Pennsylvania) first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
- Capstone Wealth Management Group (Pennsylvania)'s Regeneron Pharmaceuticals position peaked at $1.92M in Q2 2024.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Capstone Wealth Management Group (Pennsylvania)'s 13F filing for Q2 2026, filed 30 Jul 2026.